Recent 8-K filings for EVMN

• May 7, 2026, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Evommune reports Q1 net loss $21.7M; EVO756 Phase 2b data due June 2026 in CSU

  Net loss $21.7M in Q1 2026 vs $14.6M prior year; cash, equivalents and investments $307.0M as of March 31, 2026.

• March 5, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  Evommune reports Q4/FY2025 net loss $28.3M/$68.9M; positive EVO301 Ph2a data; $125M raise

  Q4 net loss $28.3M; FY net loss $68.9M vs $66.8M prior year. Revenue $13.0M FY (Maruho deal). Cash $216.7M at Dec 31, 2025.

• February 13, 2026, 6:59 PM ET other material materiality 0.75 neutral item 1.01item 3.02item 7.01item 9.01 ◈ Material Agreements ×2

  Evommune announces $125M private placement of 4.5M shares at $27.88/share

  Gross proceeds ~$125M from sale of 4,494,279 shares at $27.88 per share to institutional investors.

• February 10, 2026, 6:59 PM ET other material materiality 0.80 positive item 7.01item 8.01item 9.01

  Evommune reports positive Phase 2a top-line data for EVO301 in atopic dermatitis

  Primary endpoint met: 99.8% of posterior distribution exceeded 8% improvement threshold vs placebo.

• December 11, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Evommune reports Q3 2025 net loss $12.5M; IPO raised $172.5M, three Phase 2 readouts due in 2026

  Completed IPO in Nov 2025 of 10.78M shares at $16.00, raising $172.5M gross proceeds.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.72 · Most common event other_material

2 positive 0 negative 6 neutral

source · EVMN on sec.gov